Biogen

1316 articles with Biogen

• 

  A Roundup of Major Q2 Reports: Biogen, AstraZeneca, Pfizer and More

  8/6/2018

  The last two weeks have marked the second-quarterly financial report by numerous biopharma companies. Here’s a quick look at some of the major ones.
• 

  Biogen’s Q2 Report Gets Investors Excited Again

  7/26/2018

  Many analysts and investors were holding their breaths, waiting to see what Biogen would say at yesterday’s second-quarter financial report. The financials weren’t the focus, however, but what the Cambridge, Massachusetts biotech had to say about its pipeline, especially for Alzheimer’s disease, ...
• 

  Biogen Investors Underwhelmed by Alzheimer’s Study Update

  7/26/2018

  It’s hard to say if it was actually a wild ride after the release of Alzheimer's data, but Biogen shares dropped from $383.83 to $340.84 at the news, although it appears to be rebounding slightly.

• Eisai And Biogen Present Detailed Results From Phase II Clinical Study Of Elenbecestat In MCI And Mild To Moderate Alzheimer's Disease At Alzheimer's Association International Conference (AAIC) 2018

  7/25/2018

  Eisai Co., Ltd. and Biogen Inc. announced detailed results from a Phase II clinical study (Study 202) of the investigational oral BACE (beta amyloid cleaving enzyme) inhibitor elenbecestat (development code: E2609) at the Alzheimer's Association International Conference (AAIC) 2018

• Eisai And Biogen Announce Detailed Results Of Phase II Clinical Study Of BAN2401 In Early Alzheimer's Disease At Alzheimer's Association International Conference (AAIC) 2018

  7/25/2018

  Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, "Biogen") announced detailed results from the Phase II study (Study 201) with BAN2401, an anti-amyloid beta (Aβ) protofibril antibody

• 

  Biogen Revenue Grows 9% in 2Q, Plans to Push Ahead with Alzheimer’s and Acquired New Assets

  7/24/2018

  Biogen reported strong sales for the second quarter, with total revenues of $3.4 billion, up 9 percent compared to the same period in 2017.
• 

  High Blood Pressure Linked to Brain Lesions and Alzheimer’s in New Research

  7/12/2018

  According to a new study published in Neurology, researchers discovered increased biomarkers for Alzheimer’s in the brains of older patients with high blood pressure.
• 

  Biogen Shares Positive Results in Alzheimer's Phase II Trial

  7/6/2018

  Biogen and Eisai announced positive topline results from their Phase II clinical trial of BAN2401 in Alzheimer’s disease.

• Eisai And Biogen Announce Positive Topline Results Of The Final Analysis For BAN2401 At 18 Months

  7/6/2018

  The final analysis at 18 months of the 856 patient Phase II clinical study in early Alzheimer's disease demonstrated statistically significant slowing in clinical decline and reduction of amyloid beta accumulated in the brain

• 

  Top 10 Stories of the First Half of 2018

  7/6/2018

  It’s hard to believe 2018 is half over. There have been plenty of interesting and important stories in the biopharma space this year. Here’s a look at our top 10 stories so far, counting down from 10 to the number one story.
• 

  More than $100 Billion Spent on M&A in the First 6 Months of 2018

  7/5/2018

  So far during the first six months of the year, more than $100 billion has been spent on a myriad of acquisitions across the pharma and biotech industries.
• 

  Biogen Increases Ownership in Samsung Bioepis

  6/29/2018

  Cambridge, Massachusetts-based Biogen exercised its option to acquire additional shares of Samsung Bioepis, a joint venture with Samsung BioLogics that was founded in 2012.

• Cedilla Therapeutics Expands Leadership Team with New Appointments to Direct Biology, Drug Discovery and Proteomics

  6/28/2018

  Cedilla Therapeutics today formally announced the appointment of three vice presidents with extensive experience in drug discovery to advance the company’s mission of harnessing existing protein stability mechanisms to redirect the course of disease.

• 

  The Real Test For Gene Therapy Is Yet To Come

  6/27/2018

  It feels like we’re standing on the edge of a precipice. Despite the ho-hum recent performance of biotech stocks, amazing things are about to happen. And one of the most amazing of all is gene therapy.
• 

  The Dementia Discovery Fund Raises $350 Million from Investors AARP, NFL and Others

  6/26/2018

  The Dementia Discovery Fund (DDF), a venture capital fund focused solely on dementia-related investments, completed $350 million of fundraising. The initial target was $200 million.
• 

  Report: Commercial Viability of Gene Therapy Treatments Remain

  6/21/2018

  A new report highlights some concerns about the long-term commercial viability of game-changing gene therapies that can radically transform the lives of patients.
• 

  On “The Longest Day,” A Look at Alzheimer’s Clinical Trials

  6/21/2018

  June is Alzheimer’s & Brain Awareness Month and June 21 is dubbed “The Longest Day,” which focuses on raising awareness of Alzheimer’s disease.

• Biogen to Host Investor Webcast on Its Efforts Targeting Stroke on June 28, 2018

  6/19/2018

  Biogen announced it will host a live webcast providing an overview of its efforts targeting acute ischemic stroke on Thursday, June 28, 2018.

• 

  PTC Therapeutics Presented Updated Interim Data from SMA Clinical Trial

  6/18/2018

  PTC Therapeutics presented updated interim clinical data from Part 1 of its FIREFISH clinical trial of risdiplam (RG7916) in babies with Type 1 Spinal Muscular Atrophy.
• 

  Spotlight on Biopharma Fellowships: AbbVie and Keck Graduate Institute Launch PharmD Fellowship P...

  6/14/2018

  AbbVie and the Keck Graduate Institute (KGI) School of Pharmacy have partnered to form the first AbbVie-KGI Biopharmaceutical Industry Fellowship.